Yiqiu Liu
300 Guangzhou Road
Nanjing, 210029, China
Nanjing, 210029, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 11 publications
Targeting c-Myc enhances immunotherapy efficacy in combination with Ras inhibitor in triple-negative breast cancer.
Journal: Clinical and translational medicine
Published: May 25, 2025
AR/ERK co-targeting triggers ferroptosis via FOXC2 in triple-negative breast cancer.
Journal: Science China. Life sciences
Published: March 27, 2025
Androgen receptor interacts with c-Myc to regulate macrophage-osteoclast axis and drive bone metastasis in triple negative breast cancer.
Journal: British journal of cancer
Published: June 21, 2024
Precise nano-system-based drug delivery and synergistic therapy against androgen receptor-positive triple-negative breast cancer.
Journal: Acta pharmaceutica Sinica. B
Published: December 25, 2023
Estrogen receptor beta suppresses the androgen receptor oncogenic effects in triple-negative breast cancer.
Journal: Chinese medical journal
Published: May 31, 2023
Inhibition of MYC suppresses programmed cell death ligand-1 expression and enhances immunotherapy in triple-negative breast cancer.
Journal: Chinese medical journal
Published: December 30, 2022
Microenvironment components and spatially resolved single-cell transcriptome atlas of breast cancer metastatic axillary lymph nodes.
Journal: Acta biochimica et biophysica Sinica
Published: September 23, 2022
A six-gene signature related with tumor mutation burden for predicting lymph node metastasis in breast cancer.
Journal: Translational cancer research
Published: December 20, 2020
MYC dysfunction modulates stemness and tumorigenesis in breast cancer.
Journal: International journal of biological sciences
Published: August 03, 2020
Showing 1-11 of 11
Last Updated: 09/26/2026